Prime Medicine (PRME) Current Deferred Revenue (2024 - 2026)

Prime Medicine has reported Current Deferred Revenue for 3 years, with the latest figure at $7.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 10.88% year-over-year to $7.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 10.88% YoY), and the FY2025 full-year result was $7.8 million, up 10.32% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $7.3 million, down from $7.8 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $9.3 million in Q3 2024, with the low at $7.0 million in Q3 2025.
• Historically, Current Deferred Revenue has averaged $7.9 million across 3 years, with a median of $7.8 million in 2025.
• The largest YoY upside for Current Deferred Revenue was 10.32% in 2025 against a maximum downside of 25.1% in 2025.
• Prime Medicine's Current Deferred Revenue stood at $7.1 million in 2024, then gained by 10.32% to $7.8 million in 2025, then decreased by 6.44% to $7.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $7.3 million (Q1 2026), $7.8 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.